Antibodies specific for hypervariable regions 3 to 5 of the feline immunodeficiency virus envelope glycoprotein are not solely responsible for vaccine-induced acceleration of challenge infection in cats

Journal of General Virology

Volumn 85, Issue 7, 2004, Pages 1833-1841

  Huisman, Willem ^a   Schrauwen, Eefje J A ^a   Pas, Suzan D ^a   Karlas, Jos A ^a,b   Rimmelzwaan, Guus F ^a   Osterhaus, Albert D M E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VACCINE; DNA VACCINE; HYBRID PROTEIN; PRIMER DNA; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CAT; CONTROLLED STUDY; DISEASE COURSE; FELINE IMMUNODEFICIENCY VIRUS; HOST RESISTANCE; HUMORAL IMMUNITY; INFECTION RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; RETROVIRUS INFECTION; VACCINATION; VIRUS REPLICATION; ANIMAL; CAT DISEASE; CELL LINE; COMPLEMENTARITY DETERMINING REGION; GENETICS; IMMUNOLOGY; RESTRICTION MAPPING;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BASE SEQUENCE; CATS; CELL LINE; COMPLEMENTARITY DETERMINING REGIONS; DISEASE PROGRESSION; DNA PRIMERS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNODEFICIENCY VIRUS, FELINE; RECOMBINANT FUSION PROTEINS; RESTRICTION MAPPING; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 3342967933     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.79949-0     Document Type: Article

References (53)

1. Bendinelli, M., Pistello, M., Lombardi, S., Poli, A., Garzelli, C., Matteucci, D., Ceccherini-Nelli, L., Malvaldi, G. & Tozzini, F. (1995). Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 8, 87-112.
2. Boretti, F. S., Leutenegger, C. M., Mislin, C. & 12 other authors (2000). Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. AIDS 14, 1749-1757.
3. Boyer, V., Desgranges, C., Trabaud, M. A., Fischer, E. & Kazatchkine, M. D. (1991). Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med 173, 1151-1158.
4. de Ronde, A., Stam, J. G., Boers, P. & 8 other authors (1994). Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology 198, 257-264.
5. + T cells. Nature 417, 95-98.
6. Elyar, J. S., Tellier, M. C., Soos, J. M. & Yamamoto, J. K. (1997). Perspectives on FIV vaccine development. Vaccine 15, 1437-1444.
7. Finerty, S., Stokes, C. R., Gruffydd-Jones, T. J., Hillman, T. J., Reeves, N. A., Whiting, C. V., Schaaper, W. M., Dalsgaard, K. & Harbour, D. A. (2000). Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge. Vaccine 18, 3254-3265.
8. Finerty, S., Stokes, C. R., Gruffydd-Jones, T. J., Hillman, T. J., Barr, F. J. & Harbour, D. A. (2001). Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 20, 49-58.
9. Flynn, J. N., Cannon, C. A., Reid, G., Rigby, M. A., Neil, J. C. & Jarrett, O. (1995). Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain. Immunology 85, 171-175.
10. Garrity, R. R., Rimmelzwaan, G., Minassian, A., Tsai, W. P., Lin, G., de Jong, J. J., Goudsmit, J. & Nara, P. L. (1997). Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol 159, 279-289.
11. Giannecchini, S., Isola, P., Sichi, O., Matteucci, D., Pistello, M., Zaccaro, L., Del Mauro, D. & Bendinelli, M. (2002). AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J Virol 76, 6882-6892.
12. Gonin, P., Fournier, A., Oualikene, W., Moraillon, A. & Eloit, M. (1995). Immunization trial of cats with a replication-defective adenovirus type 5 expressing the ENV gene of feline immunodeficiency virus. Vet Microbiol 45, 393-401.
13. Hosie, M. J., Osborne, R., Reid, G., Neil, J. C. & Jarrett, O. (1992). Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 35, 191-197.
14. Huisman, W., Karlas, J. A., Siebelink, K. H., Huisman, R. C., de Ronde, A., Francis, M. J., Rimmelzwaan, G. F. & Osterhaus, A. D. (1998). Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection. Vaccine 16, 181-187.
15. Karlas, J. A., Siebelink, K. H., Peer, M. A., Huisman, W., Cuisinier, A. M., Rimmelzwaan, G. F. & Osterhaus, A. D. (1999). Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 80, 761-765.
16. Klein, D., Janda, P., Steinborn, R., Muller, M., Salmons, B. & Gunzburg, W. H. (1999). Provirus load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: influence of mismatches on quantification. Electrophoresis 20, 291-299.
17. Leutenegger, C. M., Hofmann-Lehmann, R., Holznagel, E. & 8 other authors (1998). Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins. AIDS Res Hum Retrovir 14, 275-283.
18. Leutenegger, C. M., Klein, D., Hofmann-Lehmann, R., Mislin, C., Hummel, U., Boni, J., Boretti, F., Guenzburg, W. H. & Lutz, H. (1999). Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. J Virol Methods 78, 105-116.
19. Leutenegger, C. M., Boretti, F. S., Mislin, C. N. & 10 other authors (2000). Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif. J Virol 74, 10447-10457.
20. Lombardi, S., Garzelli, C., La Rosa, C., Zaccaro, L., Specter, S., Malvaldi, G., Tozzini, F., Esposito, F. & Bendinelli, M. (1993). Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J Virol 67, 4742-4749.
21. Lombardi, S., Garzelli, C., Pistello, M. & 8 other authors (1994). A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol 68, 8374-8379.
22. Lombardi, S., Massi, C., Tozzini, F., Zaccaro, L., Bazzichi, A., Bandecchi, P., La Rosa, C., Bendinelli, M. & Garzelli, C. (1995). Epitope mapping of the V3 domain of feline immunodeficiency virus envelope glycoprotein by monoclonal antibodies. J Gen Virol 76, 1893-1899.
23. Lutz, H., Hofmann-Lehmann, R., Bauer-Pham, K. & 8 other authors (1995). FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection. Vet Immunol Immunopathol 46, 103-113.
24. Matteucci, D., Pistello, M., Mazzetti, P., Giannecchini, S., Del Mauro, D., Zaccaro, L., Bandecchi, P., Tozzini, F. & Bendinelli, M. (1996). Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies. J Virol 70, 617-622.
25. Matteucci, D., Pistello, M., Mazzetti, P., Giannecchini, S., Isola, P., Merico, A., Zaccaro, L., Rizzuti, A. & Bendinelli, M. (1999). AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. Vaccine 18, 119-130.
26. Matteucci, D., Poli, A., Mazzetti, P. & 9 other authors (2000). Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J Virol 74, 10911-10919.
27. Mitchell, W. M., Ding, L. & Gabriel, J. (1998). Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV. AIDS 12, 147-156.
28. Pancino, G., Camoin, L. & Sonigo, P. (1995). Structural analysis of the principal immunodominant domain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol 69, 2110-2118.
29. Pedersen, N. C., Ho, E. W., Brown, M. L. & Yamamoto, J. K. (1987). Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 235, 790-793.
30. Pu, R., Coleman, J., Omori, M., Arai, M., Hohdatsu, T., Huang, C., Tanabe, T. & Yamamoto, J. K. (2001). Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 15, 1225-1237.
31. Richardson, J., Moraillon, A., Baud, S., Cuisinier, A. M., Sonigo, P. & Pancino, G. (1997). Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 71, 9640-9649.
32. Richardson, J., Moraillon, A., Crespeau, F., Baud, S., Sonigo, P. & Pancino, G. (1998). Delayed infection after immunization with a peptide from the transmembrane glycoprotein of the feline immunodeficiency virus. J Virol 72, 2406-2415.
33. Richardson, J., Broche, S., Baud, S., Leste-Lasserre, T., Femenia, F., Levy, D., Moraillon, A., Pancino, G. & Sonigo, P. (2002 . Lymphoid activation: a confounding factor in AIDS vaccine development? J Gen Virol 83, 2515-2521.
34. Rimmelzwaan, G. F., Siebelink, K. H., Huisman, R. C., Moss, B., Francis, M. J. & Osterhaus, A. D. (1994). Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. J Gen Virol 75, 2097-2102.
35. Robinson, W. E., Jr, Kawamura, T., Lake, D., Masuho, Y., Mitchell, W. M. & Hersh, E. M. (1990). Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 64, 5301-5305.
36. Sanders, R. W., Schiffner, L., Master, A., Kajumo, F., Guo, Y., Dragic, T., Moore, J. P. & Binley, J. M. (2000). Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 74, 5091-5100.
37. Siebelink, C. H., Windrich, R. W., Chu, I., Groen, J., Weijer, K., UytdeHaag, F. G. & Osterhaus, A. D. (1990). An enzyme linked immunosorbent assay (ELISA) for the detection of feline immunodeficiency virus (FIV) antigen in cell culture and FIV specific antibodies in feline serum. Dev Biol Stand 72, 189-196.
38. Siebelink, K. H., Chu, I. H., Rimmelzwaan, G. F., Weijer, K., Osterhaus, A. D. & Bosch, M. L. (1992). Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat. J Virol 66, 1091-1097.
39. Siebelink, K. H., Rimmelzwaan, G. F., Bosch, M. L., Meloen, R. H. & Osterhaus, A. D. (1993). A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol 67, 2202-2208.
40. Siebelink, K. H., Huisman, W., Karlas, J. A., Rimmelzwaan, G. F., Bosch, M. L. & Osterhaus, A. D. (1995a). Neutralization of feline immunodeficiency virus by polyclonal feline antibody: simultaneous involvement of hypervariable regions 4 and 5 of the surface glycoprotein. J Virol 69, 5124-5127.
41. Siebelink, K. H., Karlas, J. A., Rimmelzwaan, G. F., Osterhaus, A. D. & Bosch, M. L. (1995b). A determinant of feline immunodeficiency virus involved in Crandell feline kidney cell tropism. Vet Immunol Immunopathol 46, 61-69.
42. Siebelink, K. H., Tijhaar, E., Huisman, R. C., Huisman, W., de Ronde, A., Darby, I. H., Francis, M. J., Rimmelzwaan, G. F. & Osterhaus, A. D. (1995c). Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 69, 3704-3711.
43. Tacnet-Delorme, P., Boyer, V., Thielens, N. M., Hernandez, J. F., Bally, I., Sim, R. B., Desgranges, C. & Arlaud, G. J. (1999). In vitro analysis of complement-dependent HIV-1 cell infection using a model system. J Immunol 162, 4088-4093.
44. Tijhaar, E. J., Huisman, W., Huisman, R. C., Siebelink, K. H., Karlas, J. A., de Ronde, A., van Herwijnen, R., Mooi, F. R. & Osterhaus, A. D. (1997). Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus. J Gen Virol 78, 3265-3275.
45. Uhl, E. W., Heaton-Jones, T. G., Pu, R. & Yamamoto, J. K. (2002). FIV vaccine development and its importance to veterinary and human medicine: a review. FIV vaccine 2002 update and review. Vet Immunol Immunopathol 90, 113-132.
46. Verschoor, E. J., Boven, L. A., Blaak, H., van Vliet, A. L., Horzinek, M. C. & de Ronde, A. (1995). A single mutation within the V3 envelope neutralization domain of feline immunodeficiency virus determines its tropism for CRFK cells. J Virol 69, 4752-4757.
47. Verschoor, E. J., Willemse, M. J., Stam, J. G. & 7 other authors (1996). Evaluation of subunit vaccines against feline immunodeficiency virus infection. Vaccine 14, 285-289.
48. Willett, B. J., Flynn, J. N. & Hosie, M. J. (1997a). FIV infection of the domestic cat: an animal model for AIDS. Immunol Today 18, 182-189.
49. Willett, B. J., Picard, L., Hosie, M. J., Turner, J. D., Adema, K. & Clapham, P. R. (1997b). Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 71, 6407-6415.
50. Wu, S. C., Spouge, J. L., Conley, S. R., Tsai, W. P., Merges, M. J. & Nara, P. L. (1995). Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. J Virol 69, 6054-6062.
51. Yamamoto, J. K., Sparger, E., Ho, E. W., Andersen, P. R., O'Connor, T. P., Mandell, C. P., Lowenstine, L., Munn, R. & Pedersen, N. C. (1988). Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 49, 1246-1258.
52. Yamamoto, J. K., Okuda, T., Ackley, C. D., Louie, H., Pembroke, E., Zochlinski, H., Munn, R. J. & Gardner, M. B. (1991). Experimental vaccine protection against feline immunodeficiency virus. AIDS Res Hum Retrovir 7, 911-922.
53. Yamamoto, J. K., Hohdatsu, T., Olmsted, R. A. & 7 other authors (1993). Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol 67, 601-605.